

CV Martin Ingelsson

Date of birth: 30 April 1965

Current employer: Uppsala University, Department of Public Health and Caring Sciences; Uppsala County Council, Uppsala University Hospital.

Exams/academic degrees:

1995 MD, Karolinska Institutet
2001 Registered physician in Sweden.
2001 PhD in Neuroscience, Karolinska Institutet
2009 Associate Professor (docent) in Experimental Geriatrics, Uppsala University
2012 Specialist in Geriatric Medicine
2016 Professor in Geriatrics, Uppsala University

Positions:

1998-2001: Internship at Karolinska University Hospital
2001-2004: Research Sabbatical, AD Research Center / Massachusetts General Hospital, Boston
2005-2012: Clinical Residency at the Geriatric Department, Uppsala University Hospital
2014-2015: Research Sabbatical as Visiting Associate Professor at Harvard Medical School, Boston
2012- 2018: Specialist in Geriatrics; Uppsala University Hospital
2018- : Consultant in Geriatrics; Uppsala University Hospital

Supervision of PhD students:

2005-2008: Co-Supervisor / Elin Blom; Uppsala University
2005-2009: Co-supervisor / Lena Skoglund; Uppsala University
2007-2011: Main supervisor / Thomas Näsström; Uppsala University
2008-2013: Main supervisor / Therese Fagerqvist; Uppsala University
2012-2017: Main supervisor / Gabriel Gustafsson; Uppsala University
2013-2018: Co-supervisor / Leire Almandoz-Gil; Uppsala University
2014-2015: Co-supervisor / Gabriel Westman; Uppsala University
2014-2018: Co-supervisor / Elisabet Nikitidou; Uppsala University
2016-2018: Co-supervisor / Payam Emami; Uppsala University
2016- : Co-supervisor / Jinar Rostami; Uppsala University
2017- : Main supervisor / Maria Pagnon; Uppsala University
2018- : Main supervisor / Evangelos Konstantinidis; Uppsala University
2018- : Main supervisor / Einar Rystedt; Uppsala University

Editorial activities / Ad hoc reviewer:

Science Transl Med, J Biol Chem, Neuron, Neurology, Lancet Neurol, Mol Therapy, PNAS, Acta Neuropath, Neurobiol Aging, PLoS One, J Alzh Dis, Mol Cell Neurosci, J Biochem Cell Biol Review, BioMed Res Internat, Int J Cell Biol Exp Neurol, Alzheimer's & Dementia, J Neurotrauma, Neurotox Res, Neurodeg Dis, Int J Ger Psych, Int J Alzh Dis, Chin J Physiol, Neurochem Int, Neurochem Res, Neurosci Lett, Chemical Science, Ann Neurol, Cell Mol Neurobiol, Alzh Dement

Other editorial roles:

2014: Main editor of "Immunotherapy and Biomarkers in Neurodegenerative Disorders" (Springer Protocols)
2015-2016: Guest editor of Special Issue on "Dynamics of extracellular vesicle communication in the nervous system" / Cellular and Molecular Neurobiology
2015- : Member of the Editorial Board for Cell Mol Neurobiol
2016- : Associate Editor for Front Neurodegen

External Grants:

2012-2014: Swedish Research Council; PI; 500 000 SEK/year

2012-2018: Swedish Alzheimer Foundation; PI; 500 000-1 000 000 SEK/year
 2012-2018: Swedish Parkinson Foundation; PI; 500 000 SEK/year
 2010-2016: Swedish Brain Foundation; PI; 250 000-500 000 SEK/year
 2014-2016: Marianne and Marcus Wallenberg Foundation; PI; 800 000 SEK/year
 2015: Parkinson Research Foundation; PI; 920 000 SEK
 2016: JPND / Swedish Research Council: 4 500 000 SEK
 2018: Torsten Söderbergs Stiftelse: 1 487 000 SEK

Thesis:

Ingelsson, M: “Molecular Aspects of Tau Proteins in AD and Frontotemporal Dementia”. Karolinska Institute, Stockholm, Sweden, defended on 09/28/2001. Faculty Opponent: Dr. Simon Lovestone, King’s College, London, UK.

Ten most important publications: (of 113 peer-reviewed original research publications and 14 peer-reviewed reviews / book chapters).

1. György, B., Lööv, C., Zaborowski, MP., Takeda, S., Kleinstiver, BP, Commins, C., Kastanenka, K., Mu, D., Volak, A., Giedraitis, V., Lannfelt, L., Maguire, CA., Joung, JK., Hyman, BT., Breakefield, XO., **Ingelsson, M.** CRISPR/Cas9 mediated disruption of the *Swedish APP* allele as a therapeutic approach for early-onset Alzheimer’s disease. *Mol Ther Nucleic Acids* 2018 *in press*.
2. Ekmark-Lewén, S., Lindström, V., Gumucio, A., Ihse, E., Behere, A., Kahle, P., Nordström, E., Eriksson, M., Erlandsson, A., Bergström, J., **Ingelsson, M.** Early fine motor impairment and behavioral dysfunction in (Thy-1)-h[A30P] alpha-synuclein mice. *Brain Behav* 2018 Feb 4;8(3):e00915.
3. Condello, C., Lemmin, T., Stöhr J, Nick, M., Wu Y, Maxwell, AM., Watts, JC., Caro, CD., Oehler, A., Keene, CD., Bird, TD., van Duinen, SG., Lannfelt, L., **Ingelsson, M.**, Graff, C., Giles, K., DeGrado, WF., Prusiner, SB. Structural heterogeneity and intersubject variability of A β in familial and sporadic Alzheimer's disease. *Proc Natl Acad Sci U S A.* 2018 Jan 8.
4. Gustafsson, G., Eriksson, F., Möller, C., Lopes da Fonseca, T., Outeiro, T., Lannfelt, L., Bergström, J., **Ingelsson, M.** Cellular uptake of α -synuclein oligomer-selective antibodies is enhanced by the extracellular presence of α -synuclein and mediated via Fc γ receptors. *Cell Mol Neurobiol.* 2017 Jan; 37(1):121-131.
5. Lindström, V., Fagerqvist, T., Nordström, E., Lord, A., Tucker, S., Andersson, J., Johannesson, M., Schell, H., Kahle, P., Möller, C., Gellerfors, P., Bergström J., Lannfelt, L., **Ingelsson, M.** Reduced pathology in transgenic mice following immunotherapy with oligomer/protofibril selective α -synuclein antibodies. *Neurobiol Dis.* 2014; 69:134-43.
6. Kalimo, H., Lalowski, M., Bogdanovic, N., Philipson, O., Bird, T.D., Nochlin, D., Schellenberg, G.D., Brundin, RM, Olofsson, T., Lalowski, M., Baumann, M., Wirths, O., Bayer, T., Nilsson, L.N.G., Basun, H., Lannfelt, L. **Ingelsson, M.** The *Arctic APP* mutation leads to AD pathology with highly variable topographic deposition of differentially truncated A-beta. *Acta Neuropathol Commun* 2013; 1(1):60.
7. Fagerqvist, T., Lindström, V., Nordström, E., Lord, A., Tucker, SME., Sahlin, C., Kasrayan, A., Andersson, J., Welander, H., Näsström, T., Holmquist, M., Schell, H., Kahle, P., Kalimo, H., Möller, C., Gellerfors, P., Lannfelt, L., Bergström, J., **Ingelsson, M.** Monoclonal antibodies selective for α -synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α -synuclein transgenic mice with the disease-causing A30P mutation. *J Neurochem* 2013; 126(1):131-44.
8. Näsström, T., Gonçalves, S., Sahlin, C., Nordström, E., Screpanti Sundquist, V., Lannfelt, L., Bergström, J., Outeiro, T.F., **Ingelsson, M.** Antibodies against α -synuclein reduce oligomerization in living cells. *PLoS One* 2011; 6(10):e27230.
9. SantaCruz, K., Lewis, J., Spire, T., Paulson, J., Kotilinek, L., **Ingelsson, M.**, Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., Forster, C., Yu, M., Orne, J., Janus, C., Mariash, A., Kuskowski, M., Hyman, B.T., Hutton, M., Ashe, K.H. Tau suppression in a neurodegenerative mouse model improves memory function. *Science* 2005; 309:476-81.
10. **Ingelsson, M.**, Fukumoto, H., Newell, K., Growdon, J.H. Hedley-Whyte, T.E., Albert, M.S., Frosch, M.P., Hyman, B.T., Irizarry, MC. Early A[β] accumulation and progressive synaptic loss, gliosis and tangle formation in AD brain. *Neurology* 2004; 62(6):925-31.